Medivir to Present Clinical Data for Fostrox at ESMO Conference
Medivir AB (NASDAQ Stockholm: MVIR) is dedicated to developing innovative cancer treatments where substantial medical needs exist. The company is thrilled to announce it will present detailed findings from the phase 1b/2a study of fostrox (fostroxacitabine) combined with Lenvima (lenvatinib). This important data will be unveiled at the upcoming European Society for Medical Oncology (ESMO) Congress.
Key Presentation Details
This presentation will center on the effectiveness of fostrox in managing advanced hepatocellular carcinoma (HCC), a significant form of liver cancer. Dr. Hong Jae Chon from CHA Bundang Medical Center in Korea will present an abstract titled, "Fostrox plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations. Results from a multi-center phase 1b/2a study." The insights shared are expected to illuminate new therapeutic strategies for HCC management.
Additionally, Medivir will host a webcast immediately following the presentation featuring Dr. Chon and Dr. Pia Baumann, Medivir's Chief Medical Officer. They will discuss the clinical findings and respond to audience questions during this interactive session, which is set for September 16 at 13:45 CET. You can find the link to the webcast on Medivir's official website.
Context and Implications of the Data
Beyond the primary results, Dr. Chon will share insights drawn from his extensive experience treating liver cancer patients. He plans to contextualize the latest findings by comparing them with current practices in second-line therapies. This discussion aims to emphasize fostrox's therapeutic potential and its wider implications for patient care.
Availability of Resources
For those who want to follow the developments closely, both the presentation and the associated poster will be made available on Medivir's website after the webcast. This ensures that stakeholders can access vital information even if they cannot attend the live session.
Understanding Fostrox
Fostrox targets liver cells using a unique mechanism that inhibits DNA replication while minimizing harm to surrounding healthy tissues. By combining a potent chemotherapy agent with a prodrug, fostrox releases the active substance primarily within the liver, potentially transforming the treatment landscape for various liver cancers. A phase 1b monotherapy study has recently concluded with promising results, and a follow-up phase 1b/2a study is ongoing for HCC.
The Urgency of Treating Primary Liver Cancer
Primary liver cancer is a critical global health concern, ranking as the third leading cause of cancer-related deaths. Hepatocellular carcinoma (HCC) is the most common type that occurs in the liver and is notably the fastest-growing cancer in certain regions. Despite advancements in therapies, the survival rates for advanced HCC remain discouragingly low, with less than 20% of patients reaching a five-year survival milestone. The complexities of HCC, with its diverse causes and absence of common genetic mutations, make developing effective targeted therapies challenging. Thus, the emergence of innovative treatments like fostrox is a crucial response to a pressing medical need.
About Medivir
Medivir is committed to pioneering drug therapies in oncology, particularly for conditions that lack adequate medical solutions. Its portfolio includes fostroxacitabine bralpamide (fostrox), which is designed to preferentially target cancer cells within the liver while minimizing side effects. Medivir's development strategies involve collaborations aimed at enhancing drug development. With a strong focus on filling gaps in treatment options, the company aims to significantly improve outcomes for patients facing liver cancers. Medivir’s stock (ticker: MVIR) trades on Nasdaq Stockholm’s Small Cap list.
Frequently Asked Questions
What is the significance of the ESMO presentation?
The ESMO presentation showcases vital clinical findings regarding the effectiveness of fostrox in liver cancer treatment, particularly for HCC.
Who will present the data on fostrox at the ESMO Conference?
Dr. Hong Jae Chon from CHA Bundang Medical Center will present the data on fostrox during the ESMO Conference.
When will the Medivir webcast take place?
The webcast is scheduled for September 16 at 13:45 CET, right after the presentation at the ESMO Congress.
What role does fostrox play in liver cancer treatment?
Fostrox is designed to selectively target liver cancer cells, aiming to enhance treatment outcomes while reducing side effects.
How can I access the presentation materials after the event?
You can find the presentation and related materials on Medivir's website after the webcast concludes.
